Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1992-4-24
|
pubmed:abstractText |
The conditions under which the absorption enhancer palmitoyl L-carnitine chloride (PCC) improved the bioavailability of the poorly absorbed antibiotic cefoxitin throughout the rat intestine has been studied. Cefoxitin alone was appreciably absorbed only in the duodenum (31% vs less than 7% elsewhere). PCC solutions (3 mg/rat, pH 4.0) enhanced cefoxitin bioavailability (F) by 0-, 22-, 16-, and greater than 32-fold in the duodenum, jejunum, ileum, and colon regions, respectively. The inability of PCC to improve F in the duodenum could not likely be attributed to enzymatic degradation of the enhancer, since coadministration with protease and esterase inhibitors produced similar results (F = 30%). Coadministration of PCC solution with cefoxitin in the unligated or ligated colon, increased F to 33 and 76%, respectively. Qualitatively similar results were seen with PCC suspensions (3 mg/rat, pH 6.0). Maintaining a high concentration of cefoxitin and PCC in a restricted region (i.e., by ligating a 2- to 3-cm section of the colon) afforded a two- to threefold advantage over an unligated colon section. The difference in cefoxitin bioavailability between ligated and unligated colon was probably due to sample spreading and subsequent/simultaneous dilution.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0724-8741
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
9
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
191-4
|
pubmed:dateRevised |
2003-11-14
|
pubmed:meshHeading |
pubmed-meshheading:1553340-Adjuvants, Pharmaceutic,
pubmed-meshheading:1553340-Animals,
pubmed-meshheading:1553340-Biological Availability,
pubmed-meshheading:1553340-Cefoxitin,
pubmed-meshheading:1553340-Chromatography, High Pressure Liquid,
pubmed-meshheading:1553340-Colon,
pubmed-meshheading:1553340-Intestinal Absorption,
pubmed-meshheading:1553340-Intestine, Small,
pubmed-meshheading:1553340-Male,
pubmed-meshheading:1553340-Osmolar Concentration,
pubmed-meshheading:1553340-Palmitoylcarnitine,
pubmed-meshheading:1553340-Rats,
pubmed-meshheading:1553340-Rats, Inbred Strains,
pubmed-meshheading:1553340-Stimulation, Chemical,
pubmed-meshheading:1553340-Suspensions
|
pubmed:year |
1992
|
pubmed:articleTitle |
Enhanced bioavailability of cefoxitin using palmitoyl L-carnitine. I. Enhancer activity in different intestinal regions.
|
pubmed:affiliation |
INTERx Research Corporation, MSDRL, Lawrence, Kansas 66047.
|
pubmed:publicationType |
Journal Article
|